Survival doubled! AstraZeneca's new gastric cancer drug sone-ve targets $5 billion in annual sales, ADC takes another step toward replacing chemotherapy.

Zhitong Finance APP has learned that AstraZeneca's (AZN.US) investigational gastric cancer drug doubled patient survival in a late-stage trial, adding momentum to another potential blockbuster drug.